For the three months ended June 30,

For the six months ended June 30,

(In thousands)

2025

2024

2025

2024

Revenue from services:

Pharmaceutical

$

—

$

—

$

—

$

—

Diagnostics

101,101

129,395

203,945

256,286

Corporate

—

—

—

—

$

101,101

$

129,395

$

203,945

$

256,286

Revenue from products:

Pharmaceutical

$

40,743

$

40,485

$

75,585

$

78,532

Diagnostics

—

—

—

—

Corporate

—

—

—

—

$

40,743

$

40,485

$

75,585

$

78,532

Revenue from transfer of intellectual property and other:

Pharmaceutical

$

14,963

$

12,306

$

27,229

$

21,054

Diagnostics

—

—

—

—

Corporate

—

—

—

—

$

14,963

$

12,306

$

27,229

$

21,054

Cost of revenue:

Pharmaceutical

$

25,022

$

23,455

$

47,836

$

45,199

Diagnostics

82,383

107,078

166,901

216,952

Corporate

—

—

—

—

$

107,405

$

130,533

$

214,737

$

262,151

Gross margin:

Pharmaceutical

$

30,684

$

29,336

$

54,977

$

54,387

Diagnostics

18,718

22,317

37,044

39,334

Corporate

—

—

—

—

$

49,402

$

51,653

$

92,021

$

93,721

Selling, general and administrative:

Pharmaceutical

$

13,197

$

14,062

$

25,907

$

29,103

Diagnostics

33,369

44,502

71,325

90,262

Corporate

13,031

10,257

21,451

19,623

$

59,597

$

68,821

$

118,683

$

138,988

Research and development:

Pharmaceutical

$

29,778

$

23,686

$

60,016

$

44,933

Diagnostics

484

386

1,022

1,052

Corporate

80

10

145

35

$

30,342

$

24,082

$

61,183

$

46,020

Amortization of intangible assets:

Pharmaceutical

$

16,415

$

16,408

$

32,525

$

32,851

Diagnostics

3,029

4,012

6,779

9,005

Corporate

—

—

—

—

$

19,444

$

20,420

$

39,304

$

41,856

Segment operating loss:

Pharmaceutical

$

(28,706

)

$

(24,820

)

$

(63,470

)

$

(52,500

)

Diagnostics

(18,164

)

(26,583

)

(42,082

)

(60,985

)

Corporate

(13,111

)

(10,267

)

(21,596

)

(19,658

)

$

(59,981

)

$

(61,670

)

$

(127,148

)

$

(133,143

)